J2KBIO Co., Ltd. (KOSDAQ:420570)
South Korea · Delayed Price · Currency is KRW 8,700.00
+450.00 (5.45%)
At close: Oct 16, 2026
J2KBIO Revenue
J2KBIO had revenue of 15.60B KRW in the quarter ending June 30, 2026, with 82.95% growth. This brings the company's revenue in the last twelve months to 43.90B, up 50.99% year-over-year. In the year 2025, J2KBIO had annual revenue of 32.97B, down -0.49%. That makes J2KBIO the 30,812th largest company in the world by revenue and 1,937th in South Korea.
Revenue (ttm)
43.90B
Revenue Growth
+50.99%
P/S Ratio
1.16
Revenue / Employee
665.14M
Employees
66
Market Cap
50.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.97B | -162.83M | -0.49% |
| Dec 31, 2024 | 33.13B | 4.66B | 16.36% |
| Dec 31, 2023 | 28.47B | 12.44B | 77.60% |
| Dec 31, 2022 | 16.03B | 1.81B | 12.75% |
| Dec 31, 2021 | 14.22B | 360.95M | 2.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 75.41B |
| Psomagen | 60.70B |
| PanGen Biotech | 14.18B |
| ADBiotech | 12.57B |
| QuadMedicine | 7.14B |
| TegoScience | 6.18B |
| HLB Pep | 5.54B |
| Parataxis Korea | 1.59B |